Quincy Siu-Chung Chu (Quincy S Chu, Quincy Chu)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Therapeutic advances in medical oncology

Current oncology reports

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Quincy Siu-Chung Chu
Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates. Current oncology reports (2023)
Roy S Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Siu-Chung Chu, Isabelle Monnet, Alfredo Sánchez, Shaker Dakhil, D Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (29) (2022)
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M Heinhuis, Michael Millward, Martijn Paul Lolkema, Sandip Pravin Patel, Paul de Souza, Matteo Duca, Curigliano Giuseppe, Armando Santoro, Takafumi Koyama, Michelle Brown, Heather Vezina, Chunsheng He, Quincy Siu-Chung Chu
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Barbara L Melosky, Parneet Cheema, Rosalyn A Juergens, Natasha B Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod, Quincy Siu-Chung Chu
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic advances in medical oncology 13 (2021)
Quincy Siu-Chung Chu
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Therapeutic advances in medical oncology 12 (2020)